Leerink Partners Remains Bullish as Teva Pharma (TEVA) Awaits IPR Ruling
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Leerink Partners reiterated an Outperform rating and $66.00 price target on Teva Pharma (NYSE: TEVA) ahead of an IPR ruling on three TEVA patents.
Analyst Jason Gerberry commented, "We continue to eagerly await the IPR (inter partes review) ruling on three TEVA patents that cover Copaxone 40mg (multiple sclerosis). Today's post grant review (PGR) decision not to review the '776 patent further strengthens TEVA’s broader IP defense strategy, but the PTAB opinion did not address any of the substantive issues relating to the IPR ruling which will occur on or before 8/25."
Shares of Teva Pharma closed at $53.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- Generics File Against New Teva Pharma (TEVA) Copaxone 40MG Patent - Evercore ISI
- Targa Resources (TRGP) PT Raised to $65 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!